So Far, So Good On EMA's PRIME, With One Caveat
This article was originally published in SRA
Executive Summary
All 18 applications1 submitted for entry into the European Medicines Agency's new PRIME (priority medicines) scheme in the month after its launch were 'in scope' and of a quality that meant the assessments could be done without the EMA having to go back to any of the applicants. 'Either you are very good or our templates are very good or both,' joked the EMA official in charge of the department responsible for developing the scheme.
You may also be interested in...
EU Accelerated Assessment Tracker
Marinus’s ganaxolone has lost its accelerated assessment status mid-review at the European Medicines Agency while Roche’s glofitamab will be fast-tracked once a filing has been made.
EU Accelerated Assessment Tracker
The EU filing for AstraZeneca’s nirsevimab is being reviewed under the accelerated pathway at the European Medicines Agency. Also, Janssen should know by now whether its planned filing for Zejula plus Zytiga will get the same treatment – as should SIFI for its planned Akantior filing.
AZ Secures EU Fast-Tack Review For Nirsevimab
There could be a regulatory decision on AstraZeneca and Sanofi's nirsevimab in the EU in H2 as a result of the European Medicines Agency speeding up its review of the marketing application for the potential new immunization against RSV in all infants.